MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi with significant participation from new and existing...

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi with significant participation from new and existing...